ADRB3 and type 2 diabetes mellitus: In a similar fashion, the development of G protein-biased β3-AR agonists that do not trigger barr2-mediated β3-AR internalization may lead to highly efficacious, novel therapeutic agents for the treatment of obesity and type 2 diabetes.